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CHALLENGING PATHOLOGIES
Endovascular management of type B aortic
dissections
Paul D. DiMusto, MD,a David M. Williams, MD,b Himanshu J. Patel, MD,a Santi Trimarchi, MD,cJonathan L. Eliason, MD,a and Gilbert R. Upchurch, Jr., MD,a Ann Arbor, Mich; and Milano, ItalyINTRODUCTION
There are approximately 9000 new cases of aortic dis-
section in the United States each year. Uncomplicated type
B aortic dissections are traditionally managed with medical
therapy, controlling blood pressure and heart rate, with
30-day mortality rates between 4% and 10%. However,
there is no consensus regarding the management of com-
plicated (ie, presenting with malperfusion or refractory
pain) type B dissections. Open surgical management of
these patients carries an excessive mortality rate. Therefore,
endovascular aortic fenestration and branch vessel stenting
to relieve malperfusion was developed as an alternative to
open surgical repair. While endovascular fenestration and
stenting relieves malperfusion, it does not prevent late
aneurysm degeneration of the aorta, which can occur in up
to 30% of patients. Recently, the use of endovascular stent
grafts to cover the primary and proximal entry tear has been
examined, with the belief that this approach treats most
cases of malperfusion and, in theory, prevents late aneurysm
formation. The objective of this article is to examine the
literature surrounding the endovascular management of
type B aortic dissections, including fenestration and stent-
ing, as well as stent graft placement.
BACKGROUND
Aortic dissection involves a tear in the intima of the
aorta, allowing blood to flow within layers of the media.
This creates a false lumen for blood flow in the intramural
space, which may compress the true lumen or extend into
branch arteries, creating malperfusion. Additionally, the
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26Sdissected aorta can chronically become aneurysmal, leading
to eventual rupture. It is estimated that dissections of the
descending thoracic aorta occur with an incidence of 2 to
3.5 cases per 100,000 person-years, with approximately
9000 reported new cases in the United States each year.1,2
Common causes of aortic dissection include connective
tissue disorders, longstanding hypertension, and trauma.3
As such, a history of hypertension is found in 80% of
patients.4
Dissections involving the thoracic aorta can be classified
according to the Stanford or the DeBakey systems. In the
Stanford classification, a type A dissection involves the ascend-
ing aorta, while a type B does not (Fig 1).Under theDeBakey
classification, a type I dissection begins in the proximal aorta
and extends distally, involving both the ascending and de-
scending thoracic aorta. A type II dissection is confined to
the ascending aorta, while a type III dissection is confined
to the descending aorta (similar to Stanford type B). Dis-
sections can also be classified temporally into acute and
chronic phases. The acute phase is defined as less than 14
days from the onset of symptoms, while a chronic dissection
is defined as more than 14 days from the onset of symp-
toms. Finally, dissections are typically classified as compli-
cated or uncomplicated, with complicated dissections in-
volving malperfusion, rupture or impending rupture,
refractory hypertension, or continued pain.5 Approxi-
mately 30% of type B dissections are complicated at initial
presentation.6
The management of an aortic dissection is based typi-
cally on the type, time course, and associated symptoms,
such as malperfusion. Both type A and B dissections require
tight blood pressure control to attempt to minimize the
extent of dissection, to decrease false lumen distention, and
to reduce the risk of aortic rupture. This is commonly done
with beta blockade, as these agents reduce the heart rate and
contractile force of the heart, while also decreasing systemic
blood pressure.4 Often, additional anti-hypertensive agents
are needed.
MANAGEMENT OF TYPE A DISSECTIONS
Acute type A dissections are a surgical emergency,
mandating replacement of the ascending aorta and some-
times aortic valve to reduce the risk of death. This can occur
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onary artery involvement in the dissection, aortic regurgi-
tation, ormalperfusion of the brain, viscera, or kidneys. The
presence of such preoperative complications defines an
unstable clinical status, which is associated with a signifi-
cantly higher in-hospital mortality when compared with
patients in stable condition (31% vs 17%, respectively).7
Despite emergent surgical management, these patients
have an overall 25% in-hospital mortality rate as reported
from the International Registry of Acute Aortic Dissection
(IRAD) database. However, for those patients discharged
alive following surgical repair of a type A dissection, long-
term survival is 96% at 1 year and 91% at 3 years.8 A review
of the Nationwide Inpatient Sample of over 3000 patients
from 1995 through 2003 found an overall 26% in-hospital
mortality for patients undergoing operative repair of type A
dissections.9 However, there was a statistically significant
decrease in hospital mortality over the course of the study,
ranging from 27% in 1995 to 23% in 2003.
Traditionally, all patients with type A dissections un-
dergo emergent surgical repair, regardless of whether the
dissection is complicated or not. However, a local paradigm
shift has occurred. Patients at our institution with a type A
dissection presenting with prolonged malperfusion of one
or more vascular beds have been shown to have an im-
proved survival when the malperfusion is corrected prior to
aortic repair. In a small initial study of patients from the
University of Michigan, Deeb and colleagues found an 11%
(1/9) survival rate to hospital discharge for patients with a
complicated type A dissection who underwent immediate
surgical repair, compared with a 75% survival rate (15/20)
for patients who had correction of their malperfusion by
endovascular fenestration and stenting (discussed below),
recovery from the malperfusion, and delayed aortic re-
pair.10 The average time to repair was 20 days. Three
patients (15%) in this group died prior to operative repair,
Fig 1. Computed tomography scan of a patient with a type B
aortic dissection.Double arrow indicates the non-dissected ascend-
ing aorta, single arrow indicates the true lumen, and F indicates the
false lumen.one from a retrograde dissection with rupture and two fromreperfusion injury. Two of the 17 patients who underwent
surgical repair (12%) died prior to hospital discharge.
In a larger follow-up study, the same group examined
196 patients admitted with type A dissections, 70 of them
with malperfusion who underwent immediate fenestration
and stentingwith delayed operative aortic repair.11 Twenty-
three patients (33%) in the malperfusion group died before
operative repair, 11 from complications of malperfusion
and 12 from aortic rupture. Of the 173 patients who
underwent operative repair, the operative mortality was
9.2%. A subgroup analysis revealed a similar mean survival
between the groups (96 months in the uncomplicated
group vs 81 months in the malperfusion group). Thus,
while this strategy still carries a high mortality rate, those
patients who survive the insult of malperfusion and make it
to operative repair have a survival rate similar to those who
present with uncomplicated type A dissections.
MANAGEMENT OF TYPE B DISSECTIONS
The management of a type B dissection classically de-
pends on whether the dissection is considered complicated
or not. For uncomplicated type B dissections, medical
management is advocated, as it has been shown to have a
lower mortality than surgical intervention, particularly in
the acute phase. Surgical intervention for uncomplicated
type B dissections is classically reserved for those patients
who develop complications in the chronic phase. Aneurys-
mal dilation of the false lumenwill develop in 20% to 50% of
patients with type B dissections within 1 to 5 years, even-
tually leading to the need for repair to prevent aortic
rupture.12,13
Complicated type B dissections, in contrast, require
intervention in the acute phase to alleviate malperfusion or
refractory hypertension. However, mortality rates for sur-
gical intervention are extremely high. The IRAD investiga-
tors reported on 82 patients undergoing open surgical
intervention for type B dissection and described an overall
in-hospital mortality rate of 29%.14 The in-hospital mortal-
ity rate was 39% for patients undergoing surgery within the
first 48 hours and 18% for those having surgery more than
48 hours after the onset of symptoms. Independent predic-
tors of surgical mortality for a type B dissection were an age
greater than 70 years and preoperative shock or hypoten-
sion. New neurological deficits were seen in 23% of pa-
tients, with 9% suffering a stroke, and approximately 5%
developing paraplegia. In 2008, the same investigators
reported an in-hospital mortality rate of 34% in 59 patients
undergoing open surgical intervention for complicated
type B dissections.6 These patients had a 40% in-hospital
complication rate with three (5%) developing paraplegia.
Endovascular fenestration and stenting. Given the
high morbidity and mortality rates associated with open
surgical intervention, less invasive alternatives were sought
to treat malperfusion associated with a complicated type B
dissection. In the 1990s, as endovascular techniques con-
tinued to evolve, the concept of endovascular fenestration
and stenting to treat malperfusion became popular.15 En-
dovascular fenestration and stenting requires extensive en-
JOURNAL OF VASCULAR SURGERY
October Supplement 201028S DiMusto et aldovascular skill and experience, but can relieve the symp-
toms of malperfusion with a lower risk of morbidity and
mortality than open surgery. The theoretical disadvantage
of this technique is that it promotes blood flow through the
false lumen, which potentially can lead to progressive dila-
tion and aneurysm development, with the possibility of
eventual rupture.16
Williams et al classified branch vessel compromise sec-
ondary to aortic dissections as either static or dynamic (Fig
2).17 Static obstruction occurs when the course of dissec-
tion intersects the origin of a branch vessel, and the aortic
hematoma propagates into that vessel wall, thereby con-
stricting the lumen. Dynamic obstruction results from pro-
lapse of the dissection flap across the branch vessel origin.
Additionally, dynamic narrowing of the aorta proximal to a
branch vessel ostium may compromise a vessel otherwise
spared by the dissection flap. Finally, a combination of any
of these mechanisms may also be present.
The technique of endovascular fenestration and stenting
begins with an angiographic evaluation (Fig 3, A) of malper-
fusion directed at finding and treating ongoing branch artery
obstructions. Intravascular ultrasound (IVUS) is performed
from the ascending aorta to the iliac arteries to define the
relationship of the dissection flap to branch arteries and to
determine the lumen from which each major branch arises
(Fig 3, B). Pressures in the superior mesenteric artery,
bilateral renal arteries, and bilateral external iliac arteries are
measured simultaneously with pressures in the aortic root.
Hand injections of contrast are performed in each branch
vessel to establish that the location of each pressure mea-
surement is peripheral to the distal extent of the false
lumen, and to examine for arteriopathy or peripheral em-
boli. In the example of branch vessel malperfusion, true
malperfusion is confirmed by a systolic gradient between
the aortic root and the superior mesenteric artery or renal
hilum of 15 mm Hg, failure of a branch artery to fill
during injection of contrast in the true and false lumen of
Fig 2. Diagram illustrating the different types of branch vessel
obstruction: static, dynamic, or both. Figure reprinted from Wil-
liams et al17 with permission.the aorta, evidence of a “curtain-like” occlusion of thevessel origin or of the true lumen above the origin by IVUS,
thrombosis, or peripheral emboli.
To perform endovascular aortic fenestration, an Am-
platz wire (Cook Medical, Bloomington, Ind) is typically
advanced through a Cobra catheter (Cook Medical). The
catheter is then withdrawn over the wire and exchanged for a
Rosch-Uchida (Cook Medical) introducer set that is subse-
quently placed in the true lumen. Thewire is removed and the
trocar, in its encasing 5 Fr catheter, is advanced and thrust
through the dissection flap using fluoroscopic and IVUS
Fig 3. A, Angiogram of a patient with a type B aortic dissection.
The arrow indicates the true lumen, which is collapsed. B, Intra-
vascular ultrasound image from the descending thoracic aorta in a
patient with a type B aortic dissection. T indicates the true lumen,
F the false lumen.guidance (Fig 4). The trocar is exchanged for the Amplatz
ure re
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fenestration tear with a 14-mm-diameter balloon.Other tech-
niques to create or enlarge the fenestration have been de-
scribed, including the use of a snare to have a stiff wire from
the arm to the groin across the fenestration, similar to
“flossing” in thoracic endografting, or using a double
wire/one sheath “push” technique. Following creation of
the tear, the configuration of the two lumens is observed
using IVUS. If the true lumen remains collapsed or, in
questionable cases, if a gradient between the root and the
abdominal aorta persists, a large-diameter (16-22 mm)
self-expanding stent is deployed entirely within the aortic
true lumen, taking care not to cover the renal or superior
mesenteric artery origins (Fig 5). The stent should not be
deployed through the fenestration tear (ie, half in the true
and half in the false lumen), which would greater compli-
cate future transfemoral cardiopulmonary bypass or trans-
femoral access to the coronary arteries due to the shunting
of blood into the false lumen through the stent. Note that
compromise of the superior mesenteric artery should be
treated before addressing compromise of the renal or iliac
arteries.5,15
If there is evidence of static obstruction, branch vessel
stenting should be attempted. A self-expanding bare stent
is deployed under fluoroscopic and, in select cases, IVUS
guidance. The stents are extended further into the aortic
lumen (up to 5-10 mm) than is necessary when treating
atherosclerotic stenoses (Fig 6).
Reassessment with IVUS and pressure measurements
must be performed before terminating the procedure, be-
cause occasionally revascularization of a major vessel in-
creases flow in the true lumen and results in proximal
collapse of the aortic true lumen with resultant dynamic
obstruction. If dynamic obstruction results secondary to
treating a branch artery narrowing, it is treated in standard
Fig 4. The technique of endovascular aortic fenestration
and false lumens. B, A wire is advanced through the pun
a 14-mm balloon.D, The resulting fenestration tear. Figfashion with fenestration and aortic stenting. Proceduralsuccess is confirmed by resolution of true lumen collapse
and elimination of, or at least significant improvement in,
aorto-branch-artery pressure gradients as determined by
IVUS, branch arteriography, and manometry.
Four studies in particular examining endovascular fen-
estration and stenting merit review. Patel et al reported on
69 patients with complicated acute type B dissection who
underwent medical management along with fenestration
and stenting at the University of Michigan.18 The median
time to intervention after onset of symptoms was 1 day.
Multiple vascular beds were affected in 70% of patients by
angiography for a total of 185 vascular beds at risk. Flow
was successfully restored in 96% of these vascular beds.
Stroke and paraplegia rates were 4.3% and 2.9% (two pa-
tients), respectively. Both patients who suffered paraplegia
had presented with paraparesis that was not improved
following the procedure. Early mortality was 17% (12 pa-
tients) with five patients sustaining aortic rupture. All-cause
mortality at mean follow-up of 42 months was 36%.
Another study from the University of Michigan exam-
ined the outcomes of 165 patients presenting with aortic
dissection, focusing on renal malperfusion.19 This study
included 56 patients with acute type A dissections, 59 with
acute type B dissections, 19 with chronic type A dissections,
and 31 with chronic type B dissections. Ninety patients
were found to specifically have renal malperfusion. A total
of 71 of these 90 patients underwent endovascular therapy
to correct the renal malperfusion, including renal artery
stenting, aortic fenestration, and stenting. A total of five
patients (7%) experienced procedure-related complica-
tions, all of which were minor. The 30-day mortality rate
was 21% (15 patients), three of whom died of aortic rup-
ture.
A study from Germany examined the role of endovas-
cular fenestration and stenting to treat ischemia in 45
A puncture is made in the membrane separating the true
into the false lumen. C, The fenestration is dilated with
printed from Patel HJ, Williams DM39 with permission.. A,
cturepatients with aortic dissection.20 Thirteen patients had type
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acute and chronic dissections. There were a total of 88
vascular beds compromised by the dissection: 33 involved
the lower extremities, 25 the renal arteries, 22 the mesen-
teric vessels, and 8 the spinal vessels. Three patients were
able to be treated with stenting alone, while the other 42
underwent fenestration and stenting. The median duration
of follow-up was 37 months. Seven of the 25 patients with
renal ischemia required dialysis, but all of the patients were
able to be weaned off dialysis within 3 months following
Fig 5. A, Diagram illustrating the proper placement of a bare
metal stent in the true lumen of the aorta. Figure reprinted from
Patel HJ, Williams DM39 with permission. B, Fluoroscopic image
of a self-expanding bare metal stent in the descending thoracic
aorta. The IVUS probe and a Cobra catheter can also be seen.intervention. Two of the eight patients (25%) with spinalcord ischemia did not have any improvement following
intervention. The 30-day mortality rate was 6.7% (three
patients), with each of these three patients having acute
dissections.
A study of long-term outcomes following endovascular
aortic fenestration of acute complicated aortic dissection
reported on 20 patients with a mean follow up of 731
days.21 Three patients had type A dissections and under-
went surgical replacement of the ascending aorta prior to
descending thoracic fenestration, while 17 had type B
dissections. Branch vessel malperfusion improved in 18 of
the patients (90%) following the procedure. Two patients
showed partial thrombosis of the false lumen on follow-up
at 1 year. Two patients died within 30 days, for a mortality
rate of 10%.
Endovascular stent graft therapy. The first feasibility
and safety trials of aortic stent grafts for use in the thoracic
aorta began in 1992, with the primary goal of treating
thoracic aortic aneurysms (TAAs). Since that time, several
different companies have developed thoracic stent grafts for
treatment of TAAs, with a number of stent grafts subse-
quently being FDA-approved for this indication only. The
concept of using an aortic stent graft to treat acute thoracic
aortic dissection was first demonstrated by Dake and col-
leagues in 1999.22 The rationale for using a stent graft in
this scenario is two-fold. First, the stent graft provides
stability to the true lumen in the acute setting, preventing
early rupture and, in some cases, relieving branch vessel
obstruction (ie, dynamic obstruction) without further in-
tervention (Fig 7). Second, covering the entry tear with a
stent graft prevents blood flow into the false lumen, thereby
allowing the true lumen to expand and promote thrombo-
sis of the false lumen through stasis (Fig 8).5 This theoret-
ically helps to prevent late complications, such as dilation of
the false lumen with possible aneurysm formation and
rupture. Even if the false lumen does not completely
Fig 6. Diagram illustrating branch vessel stenting to relieve static
obstruction. Figure reprinted from Patel HJ, Williams DM39 with
permission.thrombose, sheltering it from systemic systolic pressure
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tation.22
Single-center studies of stent-graft therapy. In the
initial report in 1999 by Dake and colleagues, aortic stent
grafts were used to cover the entry tear in 15 patients with
type B dissections, and in four patients with type A dissec-
tions with a primary entry tear in the descending thoracic
aorta who suffered retrograde dissections (Table I).22 Stent
grafts were successfully placed in all 19 patients. There was
complete thrombosis of the false lumen in 15 patients
(79%), with partial thrombosis in the other four. There
were three deaths, all with complicated type B dissections,
within the first 30 days following the procedure, for an early
mortality rate of 16%. However, there were no aneurysms,
aortic ruptures, or deaths seen in the subsequent 13months
of follow-up in the remaining patients. Additionally, there
were no cases of paralysis. Thirty-eight aortic branch vas-
cular beds were ischemic due to the dissection in these 19
patients, with 28 of them being reperfused simply by cov-
ering the entry tear with a stent graft. This study docu-
mented that the use of aortic stent grafts to cover the entry
tear in a dissection was feasible, suggesting further investi-
gation of this concept was warranted.
A report from UCLA examined the use of the
Medtronic AneuRx and Talent (Medtronic, Minneapolis,
Minn) devices for the treatment of 42 patients with type B
aortic dissections (Table I).2 There were 25 patients with
acute dissections, and 17 with chronic dissections. All pa-
tients wereASA class III. There were a total of 42 primary
procedures and 18 secondary procedures. The risk of rein-
tervention was four times higher in acute dissection com-
pared with chronic, which was significantly different. IVUS
was used in all cases to aid in placement of the endograft
and to visualize the stagnation of blood flow in the false
Fig 7. Diagram illustrating stent-graft placement in the true lu-
men of the aorta. Figure reprinted from Patel HJ, Williams DM39
with permission.lumen following endograft placement. Technical successwas achieved in 58 of the 60 procedures (97%). Thrombosis
of the false lumen was seen in 61% of patients at 1 month
and 88% at 1 year. Overall stroke rate was high at 9.5%
(4/42), with a procedural stroke rate of 6.7% (4/60).
However, none of the patients developed paraplegia. A
total of four patients developed a retrograde dissection
following endograft placement, two after the primary pro-
cedure and two after a secondary procedure, requiring
subsequent open repair with cardiopulmonary bypass.
Three of these patients died and the fourth had an anoxic
brain injury. The 30-day mortality for the entire group was
9.5% (n  4), with an additional five late deaths, for an
overall mortality rate of 21%.
Szeto et al, from the University of Pennsylvania, exam-
Fig 8. A, Angiogram image from a patient following stent graft
placement demonstrating flow through the stent graft in the true
lumen and no flow in the false lumen. B, Computed tomography
scan from the same patient demonstrating flow through the aortic
stent graft and a collapsed false lumen.ined the use of stent graft placement for the treatment of an
r Tho
ection
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I).23 Eighteen patients had evidence of rupture, while 17
had malperfusion. Technical success with coverage of the
primary entry tear was achieved in 97% (34) of the patients.
However, 12 patients (34%) required adjunct procedures,
including bare metal stents in the infrarenal aorta, renal
artery, celiac artery, or iliac artery. One patient suffered a
stroke (2.8%), two patients (5.7%) had transient paraplegia,
and one had permanent paraplegia (2.8%). The 30-day
mortality rate was 2.8% (one patient), while 1-year survival
was 93%.
Multi-center studies of stent graft therapy. A mul-
ticenter trial of the TAG device from Gore (Gore Medical,
Flagstaff, Ariz) included 19 patients with acute complicated
type B aortic dissections (Table I).24 Importantly, none of
the patients suffered paraplegia. The 30-day mortality rate
was 16% (three patients), two of whom suffered a stroke,
while one suffered aortic rupture. Seven patients had en-
doleaks following stent grafting, with two requiring revi-
sions. The 1-year mortality rate was 21%. Unfortunately,
false lumen thrombosis rate was not reported as a part of
Table 1. Trials of stent graft repair of complicated and un
Reference
No. of
patients Type
Dake22 19 4 type A, 15 type B
Leurs26 131 7 type A, 106 type B
18 N/A
Bortone34 43 43 type B
Dialetto35 28 28 type B
Eggebrecht36 38 38 type B
Eggebrecht28 (meta-analysis) 609 24 type A, 585 type
Song2 42 42 type B
Xu37 63 63 type B
Schoder38 28 28 type B
Fattori6 66 66 type B
Szeto23 35 35 type B
Parker29 942 942 type B
Kische25 180 9 type A, 171 type B
Cambria24 19 19 type B
Nienaber31 72 72 type B
EUROSTAR/UK, European Collaborators on Stent Graft Techniques fo
Endograft Registry; INSTEAD, Investigation of Stent Grafts in Aortic Diss
Table II. Comparison of percutaneous treatments of
aortic dissection
Endograft Fenestration
Indication Complicated aortic
dissection
Malperfusion
Technique Simple Complex
Time to completion Short Long
Anatomical applicability 50% Nearly 100%
Fate of false lumen Variable Persists
Adapted from Table 16.4 in Williams DM. Aortic dissection: role of fenes-
tration and stents in the endograft era. In Lumsden AB, Lin PH, Chen C,
Parodi JC, editors. Advanced endovascular therapy of aortic disease. Mal-
den, MA: Blackwell Futura; 2007.this study.The Talent Thoracic Retrospective Registry, which in-
cludes data collected from seven European referral centers,
reported on 180 patients who received a Medtronic Talent
stent graft (Medtronic) for the treatment of aortic dissec-
tion (Table I).25 This group included nine patients with
type A dissection who had already undergone open ascend-
ing aortic repair and were being treated for a chronic “type
B” dissection, and 171 patients with type B dissections, 29
of which were complicated. There was a 98% technical
success rate in stent graft deployment. Stroke and paraple-
gia rates were 3.9% (seven patients) and 2.8% (five patients),
respectively. Paraplegia resolved in two of the five patients.
Thirty-day mortality was 5% (nine patients), with an addi-
tional 11 late deaths. Overall survival was 95% at 30 days,
91% at 12 months, 91% at 24 months, and 82% at 36
months.
The data from the European Collaborators on Stent
Graft Techniques for the Thoracic Aortic Aneurysm and
Dissection Repair (EUROSTAR) and theUnited Kingdom
Thoracic Endograft registries were examined by Leurs et al
in 2004 (Table I).26 This review included 131 patients with
acute aortic dissection over a 5-year period. There were
seven patients with a type A dissection, 106 with type B,
and the classification was not available in 18. The descend-
ing thoracic aorta was involved in all patients. There was
not a significant difference between the number of emer-
gency and elective procedures performed, with 57% of
patients having symptoms at the time of the procedure.
Overall, there was an 89% primary technical success rate in
stent grafting, with the others having incomplete coverage
of the primary tear, persistent flow in the false lumen, no
expansion of the true lumen, or endoleaks. One patient
developed paraplegia (0.8%), and two had a stroke (1.5%).
The 30-day mortality rate was 8.4%, without a significant
plicated type B aortic dissections
Year
Technical
success (%)
Stroke
(%)
Paraplegia
(%)
30-day
mortality (%)
1999 100 0 0 16
2004 89 1.5 0.8 8.4
2004 100 0 0 7
2005 100 0 0 10.7
2005 100 2.6 0 2.6
2006 98 1.9 0.8 5.3
2006 97 9.5 0 9.5
2006 95 1.6 0 3.2
2007 86 0 3.6 10.7
2008 N/A 3.4 1.5 10.6
2008 97 2.8 2.8 2.8
2008 95 3.1 1.9 9
2009 98.3 3.9 2.8 5
2009 100 11 0 16
2009 100 1.5 2.8 2.8
racic Aortic Aneurysm and Dissection Repair/United Kingdom Thoracic
.com
,
Bdifference between those undergoing elective versus emer-
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90%.
Open surgery versus endovascular treatment –
IRAD. In 2006, IRAD investigators examined long-term
survival in patients who presented with an acute type B
dissection between 1996 and 2003.27 A total of 242 pa-
tients were included, with a mean follow-up time of 2.3
years. All patients had aggressive medical therapy. Twenty-
six (11%) also had open surgical intervention, while 27
(11%) received endovascular treatment. All of those who
underwent further treatment had symptoms of ischemia or
refractory pain. In-hospital mortality rate was 29% for sur-
gical intervention, 11% for endovascular therapy, and 10%
for medical management alone. The unadjusted survival
rate at 1 and 3 years for those patients discharged alive from
the hospital was 96% and 83% for surgery, 89% and 76% for
endovascular treatment, and 90% and 78% for those pa-
tients treated with medical therapy alone. Thus, the mor-
tality of an acute type B aortic dissection is relatively high,
with almost 25% of patients dying within 3 years following
discharge from the hospital, regardless of the initial therapy
they received.
The IRAD investigators reported in 2008 on 66 pa-
tients who underwent endovascular treatment of acute type
B dissections, including both fenestration and stenting
along with stent graft placement, in addition to aggressive
medical management (Table I).6 These patients were com-
pared with 59 patients who underwent open surgical treat-
ment and 390 who were managed medically. A total of 43
patients had a stent graft placed, and 23 underwent endo-
vascular fenestration. The patients who underwent endo-
vascular therapy were significantly younger (58.8 years)
than those undergoing open surgery (61.9 years) or who
had medical management (65.5 years). The in-hospital
complication rate was 21% in the endovascular group,
compared with 40% in those undergoing open surgical
treatment, which was also significantly different (P  .04).
Stroke occurred in two patients (3.4%) in the endovascular
group, compared with four (9.1%) in the surgical group.
One patient suffered paraplegia in the endovascular group
(1.5%), compared with three (5.1%) in the open repair
group. The in-hospital mortality was also higher in the
surgery group at 34%, compared with 11% in the endovas-
cular group, which was significantly different (P  .002).
The mortality rate for the group who received medical
treatment alone was 8.7%.
Meta-analyses of endovascular stent-graft the-
rapy. A meta-analysis published by Eggebrect et al reflects
the early cumulative experience with the use of stent grafts
in the treatment of aortic dissection (Table I).28 This
analysis included 39 studies published between January
1999 and May 2004, with a total of 609 patients. All
studies included greater than three patients. All patients
had an entry tear in the descending aorta, with 4% having a
retrograde type A dissection and 96% with a type B dissec-
tion. There were 248 acute dissections from the data avail-
able. Technical success in endograft placement was
achieved in 98% of patients, with 2.3% being converted toan open procedure at some point during their hospital stay.
A total of 14% of patients had in-hospital complications,
including 1.9% with retrograde extension of the dissection
and 2.9% with neurologic complications. Of those who had
neurologic complications, paraplegia occurred in 0.8% of
patients and stroke in 1.9%. The in-hospital complication
rate was higher in those undergoing stent graft placement
for acute dissection (22%) compared with chronic dissec-
tion (9%; P  .005). Overall in-hospital mortality rate was
5.2%, with one death occurring after discharge, but within
30 days, giving a 30-day mortality rate of 5.3%. At a mean
follow-up of 19.5 months, 12% of patients required rein-
tervention, with 2.5% undergoing open surgical interven-
tion. The false lumen thrombosis rate was 76%. Overall
survival was 93% at 30 days, 91% at 6months, 90% at 1 year,
and 89% at 2 years.28
A second meta-analysis encompassing the literature
from 1997 to 2007 was recently conducted (Table I).29
This analysis included 29 studies, all of which reported on
at least 10 patients, for a total of 942 patients. A technical
success rate of 95% was achieved for all of the cases, and the
conversion rate to open surgery was 0.6%. Stroke was the
most common major complication, occurring in 3.1% of
patients. Paraplegia occurred in 1.9%. Endovascular rein-
tervention was required in 7.6% of patients, and open
surgical intervention was necessary in 2.8%. In-hospital
mortality rate was 9%, while follow-up at 20 months re-
vealed a mortality rate of 12%.
Choice of endovascular fenestration and stenting
versus endograft for acute complicated dissections.
Efficacious treatment of acute complicated aortic dissection
requires accurate anatomical knowledge of the aorta,
branch arteries, limb and organ perfusion, and nature of the
complication. In most cases, this is provided by computed
tomography angiography, supplemented during the endo-
vascular treatment procedure by fluoroscopy and IVUS. In
the setting of acute complicated dissection, fenestration
and stenting (“fen-sten”) is limited to treating malperfu-
sion, but otherwise has broad anatomical application. It is
appropriate for treating malperfusion accompanying type A
as well as type B dissections. In the case of malperfusion and
type A dissection, it can be performed either preceding or
following open repair of the ascending aorta. In our expe-
rience, the only mechanism of malperfusion we have been
unable to treat, given the limitations of our current stent
technology, is the rare complication of graft kinking at the
distal anastomosis in the ascending aorta, where we have
encountered gradients as high as 40 mm Hg. The fen-sten
procedure is technically demanding and, if one is meticu-
lous about documenting pressure gradients and examining
peripheral arterial beds, time-consuming.
Endografts have broader indications for use; they are
indicated for impending rupture due to an unstable or
leaking false lumen, as well as for malperfusion. However,
currently available endografts have somewhat severe ana-
tomical constraints, reflected by trial protocol requirements
of robust landing zones and uncertain knowledge about
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retrograde extension into type A dissection.
In summary, fen-sten has narrow clinical indications,
but broad anatomical applicability, whereas stent grafts
have broad clinical indications, but narrow anatomical app-
licability (Table II). The choice of therapy for a given
patient with complicated aortic dissection therefore dep-
ends on the nature of the complication and the individual
patient’s aortic and branch artery anatomy. Treatment will
follow a decision tree similar to that in Fig 9. Whatever the
treatment choice, primary aortic treatment by fen-sten or
stent grafting, it should followed by evaluation of limb and
distal organ perfusion.
STENT GRAFTS FOR UNCOMPLICATED
CHRONIC DISSECTIONS
Given the relative success in the use of stent grafts for
acute dissection, further investigations have been con-
ducted to examine the use of endografts in chronic dissections
to prevent the late complication of aneurysm development
and rupture. A single-center report from the Cleveland Clinic
with intermediate and long-termoutcomes after the use of the
Cook Zenith TX1 and TX2 devices (CookMedical) included
25 patients with chronic dissections with aneurysm forma-
tion.30 The 1-year survival rate was 92% and the 5-year
survival rate 88%. The secondary intervention rate was 12%
at 1 year and 21% at 5 years. None of the devices migrated,
which was a problem in patients treated with other aortic
pathologies. The stroke and paraplegia rate was not re-
ported separately for patients with aortic dissections.
The Investigation of Stent Grafts in Aortic Dissection
(INSTEAD) trial31 randomized 140 patients with uncom-
plicated chronic (occurring 2 to 52 weeks before random-
ization) type B aortic dissections to endovascular stent graft
repair plus medical management versus medical manage-
ment alone (Table I). The analysis was done on an inten-
tion-to-treat basis. Seventy-two patients were randomized
Fig 9. Decision tree for endovascular treatment of aortic dissec-
tion. Figure adapted from Figure 15.5 in Williams DM.40to the endovascular group, with one death before interven-tion and one patient opting for medical management.
Sixty-eight patients were initially randomized to medical
management alone, with two opting for endovascular stent
grafting. Technical success was achieved in all 70 patients
who underwent endograft placement without a need for
conversion to an open procedure. In the medical manage-
ment group, 16% eventually required endovascular repair
and 4.4% open repair of the aorta for aneurysmal dilatation
greater than 6 cm. Two patients (2.8%) in the endovascular
group developed paraplegia with one in the medical group
(1.5%). One patient in the endovascular group also had a
stroke, for a stroke rate of 1.5%. Complete false lumen
thrombosis was seen in 91% of the patients in the endovas-
cular group. Two-year survival was 89% in the endovascular
group and 96% in the medical management group, with no
significant differences between the two groups. However,
because the death rate was lower than expected, the study
did not achieve statistical power. Further studies of this
issue need to be conducted, but based on these results, the
authors recommend reserving endovascular intervention
for those patients who develop late complications after
initial medical management.
FUTURE DIRECTIONS
Aortic stent grafts for the thoracic aorta were initially
developed to treat thoracic aortic aneurysms, which cur-
rently remains the only FDA-approved indication. Their
use to treat aortic dissections is relatively new. As manufac-
turers are developing dedicated devices tailored to this use,
they will likely become less rigid and more flexible, reduc-
ing some of the problems with stent graft migration and
collapse that have been documented.30 Additionally, the
development of branched thoracic endografts will allow
their use in the aortic arch, particularly to treat left subcla-
vian artery (LSA) involvement. The Society for Vascular
Surgery® guidelines currently recommend preoperative re-
vascularization for patients whose anatomy requires cover-
ing the LSAwith an endograft, unless the procedure is done
emergently, in which case selective revascularization of the
LSA is suggested.32 Clearly, backflow from the LSA can
cause an endoleak, and a branched endograft would elimi-
nate the need for carotid-subclavian bypass.
Another novel use of endografts in the treatment of
aortic dissection has been described by Pochettino et al
from the University of Pennsylvania.33 This technique in-
volves antegrade placement of an endograft in the descend-
ing thoracic aorta during open repair of DeBakey type I
dissections to treat the “type B” dissection that these
patients are often left with after open repair of the ascend-
ing aorta and arch. This is important, as more than 30% of
these patients will develop aneurysms of the thoracoab-
dominal aorta, eventually requiring open repair to prevent
rupture. The investigators examined the use of this tech-
nique in 36 patients, compared with 42 patients who
underwent standard open repair of the ascending aorta and
arch without treatment of the descending thoracic aorta
over the same time period. The stroke rate was 3% (one
patient) in the stent graft group and 10% (four patients) in
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arrest time in the stent graft group. Three patients (9%) had
transient paralysis in the stent graft group, compared with
one (2%) in the standard repair group; however, none of the
deficits were permanent. In-hospital mortality was 14% in
both groups. Eight of the stent graft patients required
further endovascular interventions to achieve false-lumen
thrombosis, but none required open intervention. Four
patients (11%) in the standard group eventually required
open thoracoabdominal aneurysm repair. Thus, while this
technique requires further study, initial reports seem to
suggest decreased long-term aneurysm formation rates
without an increase in short-term morbidity or mortality.
SUMMARY
The optimal treatment of aortic dissections remains a
challenging clinical dilemma. The treatment of type B
aortic dissections, particularly those presenting with malp-
erfusion, remains controversial despite recent unbridled
enthusiasm in favor of stent grafting. Open aortic fenestra-
tion and repair carries a high mortality rate, in addition to a
high stroke and paraplegia rate. Endovascular fenestration
and stenting represent a less invasive treatment option to
restore perfusion to end organs compared with open surgi-
cal repair. However, the 30-day mortality rate is still some-
what high. This treatment also does not address the late
complication of aneurysmal dilation requiring aortic repair
to prevent rupture.
The concept of using aortic stent grafts to treat type B
dissections is relatively new and continues to evolve, as
experience with this technique grows and technology im-
proves. In theory, treatment of a type B dissection with a
stent graft not only treats the dynamic malperfusion created
by the dissection, but also prevents late aneurysm degener-
ation. Based on these data, both endovascular fenestration
and stenting, as well as stent grafting, have a lower morbid-
ity and mortality rate than open surgical repair, and appear
to have complimentary roles in the treatment of this com-
plex aortic pathology.
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